Balvin H. L. Chua

Balvin H. L. Chua

Auto-generated profile, based on publicly available information

Balvin H. L. Chua

Cecile Cox Quillen Laboratory of Geriatrics, James H. Quillen School of Medicine, East Tennessee State University, Johnson City, TN 37614, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2007 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
Xingshun XuXingshun Xu
Xingshun Xu
CCChu C. Chua
Chu C. Chua
JKJiming Kong
Jiming Kong
RKRichard M. Kostrzewa
Richard M. Kostrzewa
UKUdayasankar Kumaraguru
Udayasankar Kumaraguru
BCBalvin H. L. Chua
Balvin H. L. Chua

1 October 2010 in Brain Research
Verified
Journal Article
Closed access
Xingshun XuXingshun Xu
Xingshun Xu
KCKao-Wei Chua
Kao-Wei Chua
CCChu C. Chua
Chu C. Chua
CLChun-Feng Liu
Chun-Feng Liu
RHRonald C. Hamdy
Ronald C. Hamdy
BCBalvin H.L. Chua
Balvin H.L. Chua

1 August 2008 in Brain Research
Verified
Journal Article
Closed access
Xingshun XuXingshun Xu
Xingshun Xu
CCChu Chang Chua
Chu Chang Chua
JGJinping Gao
Jinping Gao
KCKao-Wei Chua
Kao-Wei Chua
HWHong Wang
Hong Wang
BCBalvin H.L. Chua
Balvin H.L. Chua

29 January 2009 in Journal of Pineal Research
Verified
Journal Article
Closed access
PDF file
ZCZhongyi Chen
Zhongyi Chen
CCChu C. Chua
Chu C. Chua
JGJinping Gao
Jinping Gao
KCKao‐Wei Chua
Kao‐Wei Chua
YHYe‐Shih Ho
Ye‐Shih Ho
BCBalvin H. L. Chua
Balvin H. L. Chua

18 September 2008 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
CCChu Chang Chua
Chu Chang Chua
JGJinping Gao
Jinping Gao
YHYe-Shih Ho
Ye-Shih Ho
Xingshun XuXingshun Xu
Xingshun Xu
IKI-Chun Kuo
I-Chun Kuo
BCBalvin H.L. Chua
Balvin H.L. Chua
Bifunctional apoptosis regulator (BAR) is an endoplasmic reticulum protein that interacts with both the extrinsic and intrinsic apoptosis pathways. We hypothesize that over-expression of BARΔRING prevents apoptosis and injury following ischaemia/reperfusion (I/R) and attenuates doxorubicin (DOX)-induced cardiotoxicity. We generated a line of transgenic mice that carried a human BARΔRING transgene under the control of the mouse α-myosin heavy chain promoter. The RING domain, which binds ubiquitin conjugating enzymes, was deleted to prevent auto-ubiquitination of BAR and allow accumulation of the BAR protein, which binds apoptosis-regulating proteins. High levels of human BARΔRING transcripts and 42 KDa BARΔRING protein were expressed in the hearts of transgenic mice. When excised hearts were reperfused ex vivo for 45 min as Langendorff preparations after 45 min of global ischaemia, the functional recovery of the hearts, expressed as left ventricular developed pressure × heart rate, was 23 ± 1.7% in the non-transgenic hearts compared with 51.5 ± 4.3% in the transgenic hearts (P < 0.05). For in vivo studies, mice were subjected to 50 min of ligation of the left descending anterior coronary artery followed by 4 h of reperfusion. The infarct sizes following I/R injury, expressed as the percentage of the area at risk, were significantly smaller in the transgenic mice than in the non-transgenic mice (29 ± 4 vs. 55 ± 4%, P < 0.05). In hearts of mice subjected to cardiac I/R injury, BAR transgenic hearts had significantly fewer in situ oligo-ligation-positive cardiac cells (5.0 ± 0.4 vs. 13.4 ± 0.5%, P < 0.05). Over-expression of BARΔRING also significantly attenuated DOX-induced cardiac dysfunction and apoptosis. Our results demonstrate that over-expression of BARΔRING renders the heart more resistant to I/R injury and DOX-induced cardiotoxicity, and this protection correlates with reduced cardiomyocyte apoptosis.